Stockscreener 앱 받기
23.59
1.13%
-0.27
시장 영업 전:
23.80
0.21
+0.89%
전일 마감가:
$23.86
열려 있는:
$24.03
하루 거래량:
1.68M
Relative Volume:
1.87
시가총액:
$3.99B
수익:
-
순이익/손실:
$-323.01M
주가수익비율:
-10.63
EPS:
-2.22
순현금흐름:
$-272.30M
1주 성능:
+3.10%
1개월 성능:
-8.78%
6개월 성능:
-15.66%
1년 성능:
-41.57%
1일 변동 폭
$23.10
$24.42
1주일 범위
$23.10
$25.29
52주 변동 폭
$22.41
$41.38
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
23.59 | 3.99B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant's chief medical officer sells $56,782 in stock - MSN
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Peter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in Stock - MarketBeat
Immunovant's chief medical officer sells $56,782 in stock By Investing.com - Investing.com Australia
Immunovant CFO Eva Renee Barnett sells $54,756 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Bank of America Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - MarketBeat
JPMorgan Chase & Co. Lowers Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
JPMorgan Chase & Co. Sells 28,586 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.22 Average Price Target from Analysts - MarketBeat
How to Take Advantage of moves in (IMVT) - Stock Traders Daily
Insider Buying: Immunovant, Inc. (NASDAQ:IMVT) Director Buys 16,845,010 Shares of Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com
Immunovant to raise $450M from institutional investors - MSN
Immunovant Progresses in Autoimmune Therapy Development - TipRanks
Immunovant (NASDAQ:IMVT) Hits New 12-Month LowWhat's Next? - MarketBeat
Immunovant Raises $450 Million Through Share Purchase Agreement - TipRanks
Immunovant Announces $450 Million Private Placement - The Manila Times
Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - StockTitan
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $47.22 - MarketBeat
Q1 Earnings Estimate for Immunovant Issued By Zacks Research - Defense World
Immunovant CFO Eva Renee Barnett sells $98,930 in stock - Investing.com India
Immunovant CFO Eva Renee Barnett sells $98,930 in stock By Investing.com - Investing.com Australia
Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 4,105 Shares - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann Sells 5,105 Shares - MarketBeat
Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical - openPR
Immunovant stock hits 52-week low at $23.86 amid challenges By Investing.com - Investing.com Nigeria
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Immunovant (NASDAQ:IMVT) Reaches New 52-Week LowHere's Why - MarketBeat
Immunovant stock hits 52-week low at $23.86 amid challenges - Investing.com India
Myasthenia Gravis Market Poised for Significant Growth from - openPR
(IMVT) Long Term Investment Analysis - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Lowered to “Peer Perform” Rating by Wolfe Research - Defense World
Immunovant (NASDAQ:IMVT) Shares Gap DownHere's What Happened - MarketBeat
Wolfe Research Downgrades Immunovant (NASDAQ:IMVT) to Peer Perform - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Up 4.1%Here's Why - MarketBeat
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth - Yahoo Finance
Immunovant stock hits 52-week low at $24.61 amid market challenges - Investing.com Canada
RSI Alert: Immunovant (IMVT) Now Oversold - Nasdaq
Immunovant stock hits 52-week low at $24.61 amid market challenges By Investing.com - Investing.com South Africa
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) - Seeking Alpha
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):